leadf
logo-loader
ASX:OCC

Orthocell Ltd

 Receive alerts
Market:
ASX
Market Cap:
$79.46 m
Price
0.43 AUD
Change
1.18%
52 weeks high
0.53
52 weeks low
0.18
09.52

Director Interviews

In brief

Orthocell Ltd (ASX:OCC) is listed on the Australian Securities Exchange.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Orthocell makes progress with portfolio of CelGro® products within the bone tendon and nerve space
Orthocell Ltd - Orthocell to recruit experienced distribution management expert to grow CelGro® product

Snapshot

The company is well-positioned to establish its CelGro® product as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial partnering opportunities.

Open Deep dive

Latest news

Orthocell shares sharply higher on back of positive results in CelGro® nerve...

1 week, 5 days ago

Orthocell halted with clinical results pending on use of CelGro® for...

2 weeks ago

Orthocell has positive CelGro® study results published by prestigious Tissue...

on 17/9/20

Orthocell at forefront of growing market opportunity in regenerative...

on 17/9/20

Orthocell’s collagen medical device CelGro hits 300-case milestone under TGA...

on 14/9/20

Orthocell submits Australian TGA regulatory application for CelGro® nerve...

on 30/7/20

Orthocell awarded US trademark for Ortho-ATI® cell therapy for treatment of...

on 15/7/20

Orthocell rises on reporting 87.5% success rate for Ortho-ATI® cell therapy...

on 9/7/20

Watch

Orthocell Ltd - Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study Small caps Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study
1 week, 2 days ago
Orthocell Ltd - Orthocell 'in exciting regulatory phase' as it looks to drive its technologies into the US market Small caps Orthocell 'in exciting regulatory phase' as it looks to drive its technologies into the US market
on 22/9/20
Orthocell Ltd - Orthocell preparing for launch in the US for its CelGro® bone regeneration product Director Interviews Orthocell preparing for launch in the US for its CelGro® bone regeneration product
on 26/5/20
1564456719_PAUL-ORTHOCELL.jpg Director Interviews Orthocell publishes positive pre-clinical trial study for CelGro nerve repair
on 30/7/19
View all